drugset / Trial / NCT03880695
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 2
Unknown
48 enrolled
Peking University People's Hospital
Hunan Cancer Hospital · collabLiaoning Cancer Hospital & Institute · collabPeking University Cancer Hospital & Institute · collabPeking University Shougang Hospital · collabRuijin Hospital · collabThe First Hospital of Jilin University · collabTianjin Medical University Cancer Institute and Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Timeline
- Start
- 2019-03
- Primary completion
- 2021-04
- Completion
- 2021-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |